Tom Ksiazek & Gilead Sciences

Tom Ksiazek: Tom Ksiazek, a virologist and veterinarian, provides historical context on the Bundibugyo virus, having directed the United States — Centers for Disease Control and Prevention's Special Pathogens Branch when the virus was first identified in 2007.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Tom Ksiazek: Tom Ksiazek>>>, a virologist, directed the group that first identified the Bundibugyo virus during the 2007 outbreak in Uganda — Bundibugyo District>>>.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Tom Ksiazek: Tom Ksiazek>>>, a virologist, directed the group that first identified the Bundibugyo virus during the 2007 outbreak in Uganda — Bundibugyo District>>>.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.